Controversy coverage

RegulationWatch

Original reporting on regulatory enforcement, PBM conduct and governance failures across the US pharmaceutical industry.

RedFlag Index™ · PFE
Score 84 · #1 controversy exposure
7 documented cases · 4 open
View full ranking →
  1. Drug Pricing

    Public order discloses reversal of $48 million award against OptumRx

    A Florida federal court publicly released an order vacating a $48,362,033 arbitration award against OptumRx entities. The underlying decision was dated September 17.

  2. PBM Rebates

    Express Scripts settled the insulin case without paying a cent or admitting a thing.

    The FTC's order changes how Cigna's pharmacy benefit manager behaves from here. It returns nothing for the years the agency says list prices were inflated.

  3. Antitrust

    States seek approval of Sandoz settlement worth approximately $469 million

    State attorneys general sought approval of a generic-drug pricing settlement with Sandoz and Fougera. Illinois described approximately $469 million in total obligations, including $69 million for previously settling states.

  4. False Claims Act

    A jury found 3.3 million false claims at CVS's Omnicare. The $948.8 million judgment is settling for $440 million.

    Omnicare filed for bankruptcy two months after the judgment. The government now stands to collect less than half, and CVS admits nothing.

  5. State Enforcement

    Florida sues Pfizer and Albert Bourla over vaccine marketing

    Florida filed a consumer-protection lawsuit against Pfizer and its chief executive. Pfizer disputed the allegations.

  6. Opioid Litigation

    McKesson is paying up to $7.4 billion over opioid distribution, and admits nothing.

    The largest distributor's share of the national settlement runs for 18 years. None of it goes to individual patients.

  7. Drug Pricing

    CMS finalises international benchmark model for Medicare Part B drugs

    CMS finalised the GLOBE drug-payment model, with initial reporting in January 2027 and its performance period beginning April 2027. The rule is a payment-policy measure, not an enforcement finding against manufacturers.

  8. PBM Rebates

    Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.

    Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.

  9. Antitrust

    Caremark wins partial dismissal while Rxeed interference claim survives

    A New York federal judge dismissed Rxeed's antitrust and contractual-interference claims against Caremark. A claim concerning prospective business relationships remains pending.

  10. False Claims Act

    Dompé funded the charities that paid its own drug's copays. It cost $32 million.

    The company reported itself and got credit for it. The admissions it signed show how the arrangement was built around the launch of Oxervate.

  11. Drug Pricing

    Fruth reimbursement claims move to arbitration and Missouri federal court

    A West Virginia federal judge ordered arbitration of Fruth's claims against OptumRx and Caremark. Claims against Express Scripts were severed and transferred to Missouri.

  12. Anti-Kickback Statute

    Gilead paid its highest prescribers to speak. The settlement was $202 million.

    The company admitted paying doctors hundreds of thousands of dollars each. It still describes the programs as education.

  13. Drug Pricing

    Arkansas pharmacies sue Express Scripts over alleged reimbursement floor violations

    Twelve Arkansas pharmacies filed a private lawsuit against Express Scripts in Missouri state court, alleging reimbursements below Arkansas's statutory minimum. They seek damages and court-ordered changes; the filing establishes no liability.

  14. Medicare Advantage

    Cigna was accused of billing Medicare for diagnoses it could not support. It paid $172.3 million.

    The settlement includes no admission. Cigna's review found unsupported codes and it left them in place, the government said.

  15. PBM Rebates

    Sixth Circuit keeps Kentucky opioid case against PBMs in federal court

    The Sixth Circuit reversed an order returning Kentucky's opioid lawsuit against Express Scripts and OptumRx to state court. The ruling addressed jurisdiction, without deciding liability.

  16. Anti-Kickback Statute

    Pfizer paid $2.3 billion over kickbacks, then asked to pay Vyndamax patients' copays. Speaker fees are the route the law still leaves open.

    The Anti-Kickback Statute bars paying doctors to prescribe. It still permits paying them to talk about the same drug, and patients never see who was paid.

  17. False Claims Act

    Remedi SeniorCare settles federal allegations over prescriptions billed without valid orders

    The Justice Department announced that Remedi SeniorCare Holding Corporation agreed to pay more than $5.3 million to the United States over allegedly invalid prescription claims. The settlement is based on ability to pay and provides for installment payments without an admission of liability.

  18. PBM Rebates

    Caremark's "$8.5 billion" settlement is a projection. CVS pays nothing.

    The FTC closed its insulin case against CVS's pharmacy benefit manager with conduct terms the company says it largely follows already.

  19. False Claims Act

    Abbott agrees to nearly $385 million infant formula settlement

    The Justice Department announced a settlement with Abbott Laboratories over allegedly noncompliant infant formula and nutritional products purchased through government programs. Abbott denied the allegations and did not admit facts or liability.